Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea
Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET).
Key Points: Why are we doing the Study?
Top Goal: Which therapy (hydroxyurea or pegylated interferon alpha 2a (Pegasys) is more successful in achieving a complete response by LeukemiaNet Criteria
Other Key Goals:
- Partial response rate by Leukemia criteria
- Decrease JAK2-V617F Allele Burden
- Decrease Vascular Events (blood clots or bleeding)
- MPN Symptoms
- Tolerability of the therapy
- Progression of disease